Imatinib Sandoz 400 mg, film-coated tablets

( ARTG ) Imatinib Sandoz is indicated for the:,treatment of patients with chronic myeloid leukaemia (CML),treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy,treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy,treatment of adult patients with myelodysplastic/myelop​​​‍​​‍​​​​‍​​‍‍roliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, where conventional therapies have failed,treatment of adult patients with aggressive systemic mastocytosis (ASM), where conventional therapies have failed,treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL),treatment of patients with KIT (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST),adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST (see Dosage and Administration and Clinical Trials),treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).